Pharmaceutical holding Nacimbio of Rostec State Corporation will create new production facilities at NPO Microgen subsidiaries in Ufa, Perm and Tomsk. Biotechnology products, including COVID-globulin for the coronavirus infection treatment will be developed and issued there. State Development Corporation VEB.RF and Novikombank, the base bank of Rostec State Corporation, plan to provide financial support to the project.

Andrei Zagorsky, General Director of Nacimbio, the management company of Microgen, said:

Nacimbio plans to implement a large-scale investment program, which will result in creating a modern research, development and production facility for development and production release of biotechnology products important for public health on the basis of Microgen. We have already proceeded with designing new facilities; the amount of investment will be defined on the basis of this work, but even now, we estimate it at a few tens of billion rubles. We expect that the signed instrument will allow us to ensure the needed volume of investments in the future.

The investment program of the project contemplates the erection of new production facilities at Microgen subsidiaries in Ufa, Perm and Tomsk by 2025. In Perm, in particular, a new production of DTaP drugs with acellular pertussis component is planned to be arranged, and a base to consolidate domestically-produced 5- and 6-component DTaP vaccines is also planned to be created. Here, manufacturing of modern blood products, including COVID-globulin for the coronavirus infection treatment will also begin.